Back

Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diagnostic accuracy of natriuretic peptides Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Associate Professor Brendon Neuen

The George Institute for Global Health, Sydney (Australia)

Photo
Professor Peder Langeland Myhre

Oslo University Hospital Rikshospitalet, Oslo (Norway)

8 More presentations in this session

Presentation thumbnail
ESC Heart Failure Association age-adjusted natriuretic peptide thresholds for a new diagnosis of heart failure: diagnostic accuracy study
Professor C. Taylor (Birmingham, GB)
Abstract Slides Video
Presentation thumbnail
Screening for stage B heart failure in Type 2 diabetes: natriuretic peptide screening alone misses echocardiographic abnormalities
Doctor C. Chandramouli (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical diabetic cardiomyopathy
Doctor P. Gouda (Edmonton, CA)
Abstract Slides Video
Presentation thumbnail
Exploring heart failure prevalence and overlooked dimensions: a comprehensive NT Pro-BNP study in high-risk primary care patients
Professor A. Celik (Mersin, TR)
Abstract Slides Video
Presentation thumbnail
Clinical Implications of NT-proBNP trajectory following Sacubitril/Valsartan initiation
Doctor Y. Takigami (Sagamihara, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Diagnostic accuracy of natriuretic peptides

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources